DNTH: High Short Interest Meets Loose Borrow — Bears Face No Squeeze Pressure

The Street remains firmly constructive, though the most recent analyst activity is worth noting for its modesty. Wedbush's Laura Chico raised her target just a dollar, from $103 to $105, while maintaining Outperform — more of a housekeeping move than a conviction call. The bulk of the bullish target-raising happened in early March, when multiple firms lifted numbers aggressively following what appears to have been a meaningful clinical update: Raymond James upgraded to Strong Buy with a target of $123, Baird lifted to $132, and HC Wainwright pushed to $130. All 16 analyst ratings on the stock are Buys, with a mean price target of $126.38 — about 49% above the current price of $84.57. The bear case from Benzinga centres on the absence of any commercial revenue, the uncertainty around claseprubart's development path, and competition in the autoimmune space. The ORTEX short score has eased to 61.3 from a recent cluster around 64-65, driven by weakening near-term momentum signals. Factor scores are mixed: 90-day EPS momentum ranks in the 71st percentile, but 30-day momentum is in the 15th — a sharp recent deterioration that aligns with the short score slide.

Institutional flows add a layer of conviction to the bull side. FMR (Fidelity) holds 14.2% of shares and added 1.34 million shares in its most recently reported period. BlackRock added 1.26 million shares, and T. Rowe Price added 1.82 million. Sirenia Capital and Vanguard Capital Management each appear in the register as entirely new positions. Against that backdrop, recent insider activity runs the other way: the CFO Ryan Savitz sold over $7.5 million of stock in late March, and divisional head Simrat Randhawa sold a further $2.4 million on June 1. Net insider flow over 90 days shows net selling of approximately $31 million in value, even as the net share count appears positive due to option exercises. That divergence between institutional accumulation and insider selling at current levels is worth noting without over-reading it — pre-scheduled selling plans are common in clinical-stage biotech after a strong run.

The stock has gained 3.7% on the week to $84.57, with peers XENE and BCAX also nudging higher at around 0.9% and 4.7% respectively, while EDIT and VYGR slipped 6% and 4.5%. The divergent peer performance suggests the week's biotech move has been stock-specific rather than sector-driven. Earnings history is thin but notable: the four most recent print events produced moves of -2.5%, +4.6%, +1.2%, and -7.6% on day one, with no clear directional pattern.

With next earnings on the calendar for August 4 and the Phase 2 MMN data read-out for claseprubart pulled forward to the fourth quarter of 2026, the next major watch point is whether clinical signals around that data timeline begin to shift the short position — currently high but entirely comfortable to hold at near-zero carry costs.